No Abstract Staff WriterGalapagos NV's drug discovery programs got a major shot in the arm with a multitarget, potential multimillion-dollar rheumatoid arthritis deal with Johnson & Johnson unit Janssen Pharmaceutica NV.At its peak, the collaboration could bring Galapagos as much as €1 billion (US$1.43 billion) in up-front payments, license fees and milestones, and could involve as many as 15 to 19 targets.